AngioDynamics, Inc. (NASDAQ:ANGO) has received a consensus recommendation of “Hold” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $18.60.

A number of analysts recently issued reports on ANGO shares. BidaskClub raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Zacks Investment Research cut AngioDynamics from a “hold” rating to a “sell” rating in a research report on Thursday, July 20th. KeyCorp reissued a “hold” rating on shares of AngioDynamics in a research report on Friday, August 25th. Barclays PLC reduced their price objective on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 19th. Finally, Canaccord Genuity reissued a “hold” rating and set a $17.00 price objective on shares of AngioDynamics in a research report on Tuesday, July 18th.

AngioDynamics (ANGO) traded down 0.35% during trading on Friday, hitting $16.99. The stock had a trading volume of 283,374 shares. The firm’s 50 day moving average is $17.34 and its 200 day moving average is $16.38. AngioDynamics has a 1-year low of $14.80 and a 1-year high of $18.85. The firm has a market cap of $621.49 million, a price-to-earnings ratio of 124.01 and a beta of 1.12.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.04). AngioDynamics had a net margin of 1.64% and a return on equity of 4.83%. The business had revenue of $85.40 million for the quarter, compared to analysts’ expectations of $86.12 million. During the same quarter in the prior year, the firm posted $0.17 EPS. The business’s quarterly revenue was down 3.1% compared to the same quarter last year. On average, analysts anticipate that AngioDynamics will post $0.66 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “AngioDynamics, Inc. (ANGO) Receives $18.50 Consensus Price Target from Brokerages” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/angiodynamics-inc-ango-receives-18-50-consensus-price-target-from-brokerages/1608653.html.

In other news, CEO James C. Clemmer acquired 20,000 shares of AngioDynamics stock in a transaction that occurred on Thursday, July 20th. The stock was purchased at an average price of $15.64 per share, with a total value of $312,800.00. Following the completion of the transaction, the chief executive officer now owns 86,683 shares in the company, valued at $1,355,722.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO James C. Clemmer acquired 5,000 shares of AngioDynamics stock in a transaction that occurred on Friday, July 21st. The shares were purchased at an average cost of $15.79 per share, with a total value of $78,950.00. Following the transaction, the chief executive officer now owns 86,683 shares of the company’s stock, valued at approximately $1,368,724.57. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 25,316 shares of company stock valued at $396,806. Insiders own 1.80% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANGO. Royce & Associates LP lifted its position in shares of AngioDynamics by 15.8% in the second quarter. Royce & Associates LP now owns 938,148 shares of the medical instruments supplier’s stock worth $15,207,000 after buying an additional 127,836 shares during the last quarter. OppenheimerFunds Inc. lifted its position in shares of AngioDynamics by 21.8% in the first quarter. OppenheimerFunds Inc. now owns 16,130 shares of the medical instruments supplier’s stock worth $280,000 after buying an additional 2,883 shares during the last quarter. Bank of Montreal Can lifted its position in shares of AngioDynamics by 126.1% in the second quarter. Bank of Montreal Can now owns 262,846 shares of the medical instruments supplier’s stock worth $4,261,000 after buying an additional 146,583 shares during the last quarter. Highbridge Capital Management LLC acquired a new stake in shares of AngioDynamics in the first quarter worth about $419,000. Finally, Great Lakes Advisors LLC acquired a new stake in shares of AngioDynamics in the second quarter worth about $3,509,000. 95.71% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.